SG11201401519RA - Etanercept formulations stabilized with xylitol - Google Patents

Etanercept formulations stabilized with xylitol

Info

Publication number
SG11201401519RA
SG11201401519RA SG11201401519RA SG11201401519RA SG11201401519RA SG 11201401519R A SG11201401519R A SG 11201401519RA SG 11201401519R A SG11201401519R A SG 11201401519RA SG 11201401519R A SG11201401519R A SG 11201401519RA SG 11201401519R A SG11201401519R A SG 11201401519RA
Authority
SG
Singapore
Prior art keywords
xylitol
etanercept formulations
formulations stabilized
stabilized
etanercept
Prior art date
Application number
SG11201401519RA
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201401519RA publication Critical patent/SG11201401519RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11201401519RA 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol SG11201401519RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060745 WO2013059410A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol

Publications (1)

Publication Number Publication Date
SG11201401519RA true SG11201401519RA (en) 2014-07-30

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Family Applications Before (4)

Application Number Title Priority Date Filing Date
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Country Status (27)

Country Link
US (21) US9801942B2 (en)
EP (6) EP2768535A4 (en)
JP (6) JP6220789B2 (en)
KR (7) KR20140079491A (en)
CN (6) CN104010658A (en)
AR (6) AR088379A1 (en)
AU (6) AU2012326082B2 (en)
BR (6) BR112014009087A2 (en)
CA (6) CA2851635A1 (en)
CY (1) CY1121843T1 (en)
DK (1) DK2768525T3 (en)
EA (6) EA027325B1 (en)
ES (1) ES2734070T3 (en)
HK (6) HK1200718A1 (en)
HR (1) HRP20191215T1 (en)
HU (1) HUE045624T2 (en)
IL (6) IL231828A0 (en)
IN (3) IN2014CN02527A (en)
LT (1) LT2768525T (en)
MX (7) MX367054B (en)
PL (1) PL2768525T3 (en)
PT (1) PT2768525T (en)
RS (1) RS59179B1 (en)
SG (6) SG11201401562RA (en)
SI (1) SI2768525T1 (en)
TW (6) TWI644681B (en)
WO (6) WO2013059406A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
WO2013059406A1 (en) * 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
EP2869817A4 (en) * 2012-07-09 2016-04-06 Coherus Biosciences Inc Stable aqueous formulations of etanercept
BR112015005161A2 (en) * 2012-09-11 2017-07-04 Coherus Biosciences Inc correctly folded etanercept in high purity and excellent yield
EP2991668A1 (en) * 2013-05-02 2016-03-09 Mabxience, S.A. Alternative formulations for tnfr: fc fusion polypeptides
WO2015056613A1 (en) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Stabilized polypeptide aqueous preparation
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
CA2930227C (en) 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (en) * 2014-05-14 2018-12-15 Calor ehf A peptide or protein stabilizing formulation
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2016080367A1 (en) * 2014-11-18 2016-05-26 塩野義製薬株式会社 Stable peptide composition
WO2016102328A1 (en) * 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
KR102018608B1 (en) * 2014-12-31 2019-09-06 주식회사 엘지화학 A method for preparing TNFR-Fc fusion protein comprising impurities with predetermined content
CN104694355B (en) * 2015-03-20 2016-09-28 吉林大学 Radix Puerariae liver-protection health-care wine and preparation method thereof
MX2015010517A (en) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Etanercept composition having improved stability.
JP5938762B1 (en) * 2015-09-01 2016-06-22 日揮株式会社 Microcapsule preparation and production method thereof
CN105748414A (en) * 2016-03-02 2016-07-13 张光泉 Anti-infection micafungin freeze-drying composition and preparation method thereof
JPWO2017179683A1 (en) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Stabilized pharmaceutical composition of Micafungin
BR112019007858A2 (en) * 2016-10-21 2019-07-02 Amgen Inc pharmaceutical formulations and methods for producing the same
KR20180046888A (en) 2016-10-28 2018-05-09 (주)셀트리온 Stable Pharmaceutical Formulation
MX2017013995A (en) * 2017-10-31 2019-05-01 Probiomed S A De C V Stable pharmaceutical formulation of a fusion protein.
CN109350740B (en) * 2017-11-30 2023-06-20 百奥泰生物制药股份有限公司 Liquid preparation of humanized antibody for treating IL-6 related diseases
KR20230021164A (en) * 2017-12-22 2023-02-13 삼성바이오에피스 주식회사 Liquid composition comprising vegf antagonist
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (en) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2023502777A (en) * 2019-11-26 2023-01-25 コメラ ライフ サイエンシズ，インコーポレイテッド Excipient compounds for biopolymer formulations
AU2022223669A1 (en) 2021-02-17 2023-08-03 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (en) * 2022-01-25 2023-04-14 江苏广承药业有限公司 Loratadine liquid preparation

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (en) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02007683A (en) 2000-02-10 2002-12-13 American Home Prod Method of treating or inhibiting cellular injury or cell death.
PT1314437E (en) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Stabilized antibody-containing preparations
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
ATE394123T1 (en) 2003-02-28 2008-05-15 Ares Trading Sa LIQUID FORMULATIONS OF THE TUMOR NECROSIS FRACTOR BINDING PROTEIN TBP-1
WO2004082715A1 (en) 2003-03-20 2004-09-30 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
WO2005012353A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
DK1680137T3 (en) 2003-10-14 2013-02-18 Hoffmann La Roche Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication
JP5554466B2 (en) 2004-03-01 2014-07-23 味の素株式会社 Anti-human TNF-α antibody activity decrease inhibitor
EP2540815A1 (en) 2004-03-05 2013-01-02 DSM IP Assets B.V. Perfusion cell culture
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (en) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
AU2006256041B2 (en) * 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
CN101822820A (en) 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 Stable protein formulations
US7390786B2 (en) * 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
WO2007109254A2 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN103540575A (en) * 2006-08-01 2014-01-29 奇尼塔二有限责任公司 Pharmaceutical manufacturing methods
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
MX2009004519A (en) 2006-11-03 2009-05-12 Wyeth Corp Glycolysis-inhibiting substances in cell culture.
JP5577098B2 (en) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド Stable buffered formulations containing polypeptides
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
WO2008157356A2 (en) * 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
NZ709704A (en) 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
SG2013054218A (en) * 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
MX2010009398A (en) 2008-02-29 2010-11-12 Biogen Idec Inc Purified immunoglobulin fusion proteins and methods of their purification.
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP3760712A1 (en) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
JP6023715B2 (en) 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド Protein purification method
ES2759931T3 (en) * 2011-04-20 2020-05-12 Sandoz Ag Stable Pharmaceutical Liquid Formulations of Fusion Protein TNFR: Fc
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP2726081A4 (en) 2011-06-29 2015-04-15 Insite Vision Inc Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
CN107988166B (en) 2011-07-01 2022-03-15 美国安进公司 Mammalian cell culture
JP6463968B2 (en) 2011-07-01 2019-02-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Tumor necrosis factor receptor without arginine: FC fusion polypeptide composition and methods of use thereof
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
KR101454316B1 (en) 2011-08-17 2014-10-27 한화케미칼 주식회사 Method for Preparing Active Form of TNFR-Fc Fusion Protein
WO2013059406A1 (en) * 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
BR112015005161A2 (en) 2012-09-11 2017-07-04 Coherus Biosciences Inc correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
LT2768525T (en) 2019-09-25
JP6220789B2 (en) 2017-10-25
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
CN104011073A (en) 2014-08-27
EA028520B1 (en) 2017-11-30
PT2768525T (en) 2019-07-17
AR088379A1 (en) 2014-05-28
US10376588B2 (en) 2019-08-13
WO2013059406A1 (en) 2013-04-25
TW201325607A (en) 2013-07-01
TWI595883B (en) 2017-08-21
HK1200721A1 (en) 2015-08-14
KR20140079491A (en) 2014-06-26
AR088380A1 (en) 2014-05-28
MX367054B (en) 2019-08-02
HRP20191215T1 (en) 2019-10-04
BR112014009031A2 (en) 2017-05-09
AR088382A1 (en) 2014-05-28
EP2768525B1 (en) 2019-06-19
CN103998060B (en) 2016-12-21
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
TW201325610A (en) 2013-07-01
MX2014004726A (en) 2015-05-15
MX2014004734A (en) 2015-05-15
IL231828A0 (en) 2014-05-28
US9943601B2 (en) 2018-04-17
AU2012326168A1 (en) 2014-04-24
MX2019009176A (en) 2019-10-07
US20130101584A1 (en) 2013-04-25
JP6113176B2 (en) 2017-04-12
TWI644681B (en) 2018-12-21
BR112014009146A8 (en) 2017-06-20
US9770510B2 (en) 2017-09-26
CY1121843T1 (en) 2020-07-31
MX2014004728A (en) 2015-05-15
CA2851651A1 (en) 2013-04-25
US20190314499A1 (en) 2019-10-17
JP6104922B2 (en) 2017-03-29
SG11201401576WA (en) 2014-10-30
EP2768525A4 (en) 2015-07-15
CN103998060A (en) 2014-08-20
EA025267B1 (en) 2016-12-30
US9302002B2 (en) 2016-04-05
JP2014530256A (en) 2014-11-17
IL231829A0 (en) 2014-05-28
JP2014530864A (en) 2014-11-20
EP2768533A1 (en) 2014-08-27
BR112014009131A2 (en) 2017-06-13
KR20140091707A (en) 2014-07-22
RS59179B1 (en) 2019-10-31
SG11201401567YA (en) 2014-07-30
US10888619B2 (en) 2021-01-12
AU2012326080B2 (en) 2017-02-16
AR088383A1 (en) 2014-05-28
SG11201401563SA (en) 2014-09-26
TWI619504B (en) 2018-04-01
CA2851639A1 (en) 2013-04-25
BR112014009087A2 (en) 2017-04-18
EP2768535A4 (en) 2015-03-11
BR112014009131A8 (en) 2017-06-20
EP2768525A1 (en) 2014-08-27
KR20140091705A (en) 2014-07-22
SI2768525T1 (en) 2019-10-30
EP2768854A1 (en) 2014-08-27
EA201490803A1 (en) 2014-09-30
WO2013059408A1 (en) 2013-04-25
US10987405B2 (en) 2021-04-27
HK1200718A1 (en) 2015-08-14
JP2014530255A (en) 2014-11-17
EA027325B1 (en) 2017-07-31
KR20200008021A (en) 2020-01-22
US20190290766A1 (en) 2019-09-26
SG11201401517VA (en) 2014-09-26
KR20140091706A (en) 2014-07-22
US20190290768A1 (en) 2019-09-26
AU2012326084B2 (en) 2016-12-15
BR112014009073A2 (en) 2017-05-09
CN104010657A (en) 2014-08-27
TW201325611A (en) 2013-07-01
IL231827A0 (en) 2014-05-28
CA2851646A1 (en) 2013-04-25
JP6199298B2 (en) 2017-09-20
US20190314500A1 (en) 2019-10-17
US20130108633A1 (en) 2013-05-02
JP2014530862A (en) 2014-11-20
US11129876B2 (en) 2021-09-28
BR112014009146A2 (en) 2017-06-13
AU2012326084A1 (en) 2014-04-17
ES2734070T3 (en) 2019-12-04
JP6220788B2 (en) 2017-10-25
JP2014530254A (en) 2014-11-17
EP2768535A1 (en) 2014-08-27
US20190184017A1 (en) 2019-06-20
MX2014004725A (en) 2015-02-05
EP2768532A1 (en) 2014-08-27
EA201490801A1 (en) 2014-09-30
HK1200720A1 (en) 2015-08-14
DK2768525T3 (en) 2019-07-22
US10980885B2 (en) 2021-04-20
CA2851639C (en) 2020-12-29
TW201325609A (en) 2013-07-01
EP2768533A4 (en) 2015-03-11
AU2012326168B2 (en) 2016-12-15
KR20140097184A (en) 2014-08-06
EP2768531A1 (en) 2014-08-27
KR102068462B1 (en) 2020-01-22
AU2012326171A1 (en) 2014-04-24
CN104010658A (en) 2014-08-27
AU2012326170A1 (en) 2014-04-24
IL231826A0 (en) 2014-05-28
IL231824A0 (en) 2014-05-28
US10980884B2 (en) 2021-04-20
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (en) 2015-06-26
TW201325606A (en) 2013-07-01
EA201490802A1 (en) 2014-08-29
MX2014004732A (en) 2015-05-15
AU2012326082A1 (en) 2014-04-24
US11135267B2 (en) 2021-10-05
US20130108632A1 (en) 2013-05-02
EA025663B1 (en) 2017-01-30
US20180125982A1 (en) 2018-05-10
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
IN2014CN02592A (en) 2015-09-04
US20190298837A1 (en) 2019-10-03
US20200405865A1 (en) 2020-12-31
HUE045624T2 (en) 2020-01-28
US20190290765A1 (en) 2019-09-26
US20130101640A1 (en) 2013-04-25
EP2768531A4 (en) 2015-03-11
CA2851628A1 (en) 2013-04-25
BR112014009022A2 (en) 2017-05-02
EP2768532A4 (en) 2015-03-11
CN104011073B (en) 2017-08-25
AU2012326171B2 (en) 2017-03-09
HK1200722A1 (en) 2015-08-14
EA201490817A1 (en) 2014-09-30
JP2014530863A (en) 2014-11-20
CN104010654A (en) 2014-08-27
US20180193463A1 (en) 2018-07-12
US20190216930A1 (en) 2019-07-18
CN103998061A (en) 2014-08-20
AR088460A1 (en) 2014-06-11
CA2851642A1 (en) 2013-04-25
AU2012326082B2 (en) 2016-12-15
KR102163150B1 (en) 2020-10-08
HK1200851A1 (en) 2015-08-14
CA2851635A1 (en) 2013-04-25
EA201490815A1 (en) 2014-09-30
US10213508B2 (en) 2019-02-26
EA026410B1 (en) 2017-04-28
US20190314498A1 (en) 2019-10-17
IN2014CN02527A (en) 2015-06-26
US10772963B2 (en) 2020-09-15
PL2768525T3 (en) 2019-10-31
EP2768854A4 (en) 2015-03-11
KR20140083037A (en) 2014-07-03
US20160317667A1 (en) 2016-11-03
AU2012326170B2 (en) 2016-12-22
SG11201401562RA (en) 2014-09-26
JP6110393B2 (en) 2017-04-05
MX2014004733A (en) 2015-05-15
AU2012326080A1 (en) 2014-04-24
US20190290767A1 (en) 2019-09-26
WO2013059412A1 (en) 2013-04-25
US20160199489A1 (en) 2016-07-14
WO2013059407A1 (en) 2013-04-25
EA201490804A1 (en) 2014-09-30
IL231825A0 (en) 2014-05-28
TW201325608A (en) 2013-07-01
CN104010654B (en) 2017-10-27
US9801942B2 (en) 2017-10-31
AR088381A1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
HK1200721A1 (en) Etanercept formulations stabilized with xylitol
LT3091029T (en) Anti-il13 antibody formulations
HRP20181896T1 (en) Pharmaceutical formulations
ZA201308061B (en) Otamixaban formulations with improved stability
GB201110278D0 (en) Formulations
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201102795D0 (en) Formulations
GB201111577D0 (en) Pharmaceutical formulations